Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer

BACKGROUND: Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases. METHODS: In this multicenter phase I dose-escalation study including a phase II li...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Mross, Klaus, Frost, Annette, Scheulen, Max E, Krauss, Jürgen, Strumberg, Dirk, Schultheiss, Beate, Fasol, Ulrike, Büchert, Martin, Krätzschmer, Jörn, Delesen, Heinz, Rajagopalan, Prabhu, Christensen, Olaf
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2011
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170612/
https://ncbi.nlm.nih.gov/pubmed/21801343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2045-824X-3-16
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares